Bausch Health Companies Inc. (NYSE:BHC) Receives $7.33 Consensus Target Price from Analysts

Shares of Bausch Health Companies Inc. (NYSE:BHC) have received a consensus rating of “Hold” from the six ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $7.33.

BHC has been the topic of several recent research reports. Truist Financial lowered their price objective on Bausch Health Companies from $8.00 to $7.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Wednesday, September 25th. Piper Sandler cut shares of Bausch Health Companies from a “neutral” rating to an “underweight” rating and reduced their price objective for the company from $9.00 to $3.00 in a research note on Friday, August 2nd. Raymond James initiated coverage on shares of Bausch Health Companies in a report on Wednesday, July 10th. They set a “market perform” rating and a $8.00 target price for the company. Finally, Scotiabank cut their price target on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating on the stock in a research note on Friday, August 2nd.

Bausch Health Companies Stock Up 3.6 %

Shares of NYSE:BHC opened at $8.24 on Tuesday. The firm has a market cap of $2.97 billion, a P/E ratio of -6.64 and a beta of 0.77. Bausch Health Companies has a 12 month low of $3.96 and a 12 month high of $11.46. The company’s 50-day moving average price is $6.77 and its two-hundred day moving average price is $7.16.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 742.06%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.33 billion. During the same quarter last year, the business posted $0.81 earnings per share. As a group, equities analysts predict that Bausch Health Companies will post 3.61 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Seana Carson sold 13,370 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $6.21, for a total transaction of $83,027.70. Following the sale, the executive vice president now owns 435,198 shares of the company’s stock, valued at approximately $2,702,579.58. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 8.12% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bausch Health Companies

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Bausch Health Companies by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 11,713,993 shares of the company’s stock worth $124,285,000 after purchasing an additional 114,862 shares in the last quarter. Natixis increased its position in shares of Bausch Health Companies by 14.3% during the first quarter. Natixis now owns 3,652,200 shares of the company’s stock worth $38,707,000 after acquiring an additional 456,000 shares in the last quarter. Hillsdale Investment Management Inc. raised its holdings in shares of Bausch Health Companies by 1,050.8% during the first quarter. Hillsdale Investment Management Inc. now owns 3,409,383 shares of the company’s stock worth $36,135,000 after acquiring an additional 3,113,123 shares during the period. Dimensional Fund Advisors LP lifted its position in Bausch Health Companies by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,165,512 shares of the company’s stock valued at $22,063,000 after acquiring an additional 341,936 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its stake in Bausch Health Companies by 111.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock worth $16,612,000 after purchasing an additional 1,252,834 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.